*Purpose: An increasing body of evidence has emerged on the role of 1α,25-dihydroxyvitamin D₃[1,25(OH) 2 D] in cell differentiation, which seems to have regulation properties of proliferative action on various cell types. Posttransplant malignancies (PTM) are higher in kidney transplant recipients (KTR), with insufficient levels of inactive Vitamin D3 (25OH-D, Calcidiol). However, our group did not find relations between levels of 25-OH Vit D and PTM as in general population does. Our aim is to study if the oral administration of Calcidiol is associated with less incidence of PTM.

*Methods: An open label, case-control, retrospective study, including 738 kidney transplanted (KT) patients in our center between 2003 and 2009 with a minimum follow-up of 5 years. Random Calcidiol oral reposition was done from 2010. Group VitD (n=129; dose:266 biweekly or monthly) and Control Group (n=609, never received vitD supplementation) were assigned retrospectively. Study was approved by the Research Ethical Committee.

*Results: 148 de novo neoplasia in 123 patients, being skin cancer the most incidence (54%). Incidence of PTM was 15.67% per year, and medium time to develop PTM was 5.6±2.1 years. No statistical differences in sex, CKD etiology, immunosuppressive treatment was observed in all patients. Serum levels of 25OH-D or calcium were not associated either. After the initiation of Calcidiol reposition period, 68 patients developed cancer, 65 in the group of no vit D reposition and only 3 patients (all cases skin cancer at 4,5, and 40 months after starting Calcidiol) in the vit D group (p<0.05). Medium time for treatment with Calcidiol was 30±16 months, and the main side effect was asymptomatic hypercalcemia.

*Conclusions: Reposition with Calcidiol seems to benefit KT by reducing the incidence of cancer development, mainly in skin cancer.

« Back to 2019 American Transplant Congress